10:44 AM EDT, 07/11/2024 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) said Thursday it will work with the National Cancer Institute on a trial aimed at helping accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome.

The myeloMATCH precision medicine umbrella trial will test patients' bone marrow and blood for certain genetic biomarkers using Thermo Fisher's next-generation sequencing technology, the company said.

The study seeks to complete genomic testing and deliver complete results within a few days across testing modalities to help match patients with specific sub-studies across clinical sites in the US and Canada based on their biomarker profile, the company added.

Thermo Fisher shares were up 2.1% in recent trading.

Price: 547.99, Change: +11.12, Percent Change: +2.07